1 citations
,
October 2022 in “Дерматовенерология Косметология” This article reviews skin toxicity classifications and management in patients undergoing molecularly targeted therapy, noting significant dermatotropic side effects associated with Epidermal Growth Factor Receptor Inhibitors.
29 citations
,
July 2009 in “BJU international” This review examines the pharmacological properties and potential clinical benefits of 5α‐reductase inhibition in prostate cancer but reports no new research findings.
November 2015 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” This paper discusses the role of the National Alopecia Areata Foundation in advancing research on alopecia areata, emphasizing genetic and immunological factors, and reports no new clinical findings.
1 citations
,
May 2023 in “Prospects in Pharmaceutical Sciences” This study reviews current treatments for alopecia areata, highlighting that despite various options like corticosteroids and immunosuppressives, their limited efficacy and potential side effects are challenges, while targeting specific cytokines has shown promise except with TNF inhibitors, which may worsen the condition.
2 citations
,
March 2019 in “American journal of physiology. Renal physiology./American journal of physiology. Renal physiology” This paper discusses the potential of targeting fibrosis in addressing lower urinary tract symptoms associated with benign prostatic hyperplasia, but it provides no new clinical findings and highlights the need for further research.